Board Transition

RNS Number : 6732A

Oxford BioDynamics PLC

31 May 2019

 

31 May 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Transition

Alison Kibble steps down from OBD Board after 11 years' service

Further to the announcement of 11 January 2019, Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that Alison Kibble has today stepped down from the Board as Non-Executive Director.

Alison first joined OBD's Board in December 2007 as a representative of the University of Oxford and since the Company's IPO has served as Chair of the Audit Committee and as a member of the Nomination and Remuneration Committees.

Following Alison's stepping down, membership of the sub-committees of the Board is as follows:

Sub-committee	Chair	Other members
Audit committee	David Holbrook	Peter Pack
Nomination committee	Stephen Diggle	David Holbrook Christian Hoyer Millar
Remuneration committee	Peter Pack	David Holbrook

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

"On behalf of the Board I would like to thank Alison for her many years of service to OBD. It has been a pleasure to work with her since the Company was spun out of the University of Oxford in 2007. Alison has offered the Executive Directors consistent support and challenge throughout her tenure as a Non-Executive Director, benefiting the Company and its shareholders. We will miss her, and wish her every future success."

Alison Kibble added:

"It has been a real privilege to be part of the team that has seen OBD grow from a small company into a successful listed entity with world-class technology and partnerships with major pharma and institutions. I wish the Board and all the employees well as they take the Company forward into the next exciting phase."

-ENDS-

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Advisor and Broker Stephane Auton Edward Mansfield	[phone]
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins	[phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

BOALLFSRERIIVIA